Loading...
•
Sep 30, 2021
Zentalis Q3 2021 Earnings Report
Announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments.
Key Takeaways
Zentalis Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma and the ongoing enrollment in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC). The company's cash, cash equivalents, and marketable securities totaled $366.8 million as of September 30, 2021.
Initiated a Phase 1/2 trial of ZN-c3 in combination with gemcitabine for patients with relapsed or refractory osteosarcoma.
Enrollment is ongoing in the potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC).
Published seminal research on the discovery of ZN-c3 in the Journal of Medicinal Chemistry.
The Company’s virtual R&D day will be hosted on Thursday, December 16, 2021 at 11:00 a.m. EST
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of September 30, 2021 will be sufficient to fund operating expenses and capital expenditures requirements into the third quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...